title: Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
abstract: The aim of this study was to estimate the prognostic factors for the outcomes of chronic myeloid leukemia (CML) patients receiving allogeneic stem cell transplantation (SCT) in chronic phase (CP) in the era of tyrosine kinase inhibitors (TKIs). Ninety-seven patients who underwent allogeneic SCT in CP were analyzed. Forty-seven were TKI-naïve at the time of transplant, and 50 received TKI(s) treatment before transplantation. After a median follow-up of 115.8 months, the 4-year overall survival and event-free survival were 80.4 and 58.8%, respectively. Multivariate analysis showed that there were no differences in survival outcomes based on prior TKI therapy. Older age was a prognostic factor for higher treatment-related mortality (TRM), and the type of graft source and younger age were associated with relapse, but prior TKI therapy and disease status at the time of transplant were not associated with either TRM or relapse. Additionally, a major molecular response at 1 month and an MR(4.5) at 3 months were important predictors of favorable long-term outcomes. This study demonstrates the prognostic factors for the outcomes of allogeneic SCT in CP CML and shows that survival outcomes were not affected by the administration of long-term multi-TKI treatment prior to transplantation.
authors.forename: Sung-Eun
authors.initials: SE
authors.lastname: Lee
authors.forename: Soo Young
authors.initials: SY
authors.lastname: Choi
authors.forename: Soo-Hyun
authors.initials: SH
authors.lastname: Kim
authors.forename: Eun-Jung
authors.initials: EJ
authors.lastname: Jang
authors.forename: Ju-Hee
authors.initials: JH
authors.lastname: Bang
authors.forename: Ji-Young
authors.initials: JY
authors.lastname: Byeun
authors.forename: Jin Eok
authors.initials: JE
authors.lastname: Park
authors.forename: Hye-Rim
authors.initials: HR
authors.lastname: Jeon
authors.forename: Yun Jeong
authors.initials: YJ
authors.lastname: Oh
authors.forename: Seung-Ah
authors.initials: SA
authors.lastname: Yahng
authors.forename: Byung-Sik
authors.initials: BS
authors.lastname: Cho
authors.forename: Ki-Sung
authors.initials: KS
authors.lastname: Eom
authors.forename: Yoo-Jin
authors.initials: YJ
authors.lastname: Kim
authors.forename: Seok
authors.initials: S
authors.lastname: Lee
authors.forename: Chang-Ki
authors.initials: CK
authors.lastname: Min
authors.forename: Hee-Je
authors.initials: HJ
authors.lastname: Kim
authors.forename: Jong-Wook
authors.initials: JW
authors.lastname: Lee
authors.forename: Woo-Sung
authors.initials: WS
authors.lastname: Min
authors.forename: Chong-Won
authors.initials: CW
authors.lastname: Park
authors.forename: Dong-Wook
authors.initials: DW
authors.lastname: Kim
mesh_terms: D000293:Adolescent; D000328:Adult; D002908:Chronic Disease; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy / Q000201:enzymology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012189:Retrospective Studies; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D047428:Protein Kinase Inhibitors
keywords: Allogeneic stem cell transplantation; Chronic myeloid leukemia; Tyrosine kinase inhibitor